COST-EFFECTIVENESS OF IMATINIB AS ADJUVANT TREATMENT FOR RESECTED GASTROINTESTINAL STROMAL TUMORS (GIST) VERSUS BEST SUPPORTIVE CARE: CANADIAN PERSPECTIVE

被引：0
|
作者：
El Ouagari, K. [1 ]
Pawar, V [2 ]
Coombs, J. [3 ]
Rubin, J. [2 ]
机构：
[1] Novartis Pharmaceut Canada, Dorval, PQ, Canada
[2] I3 Innovus, Medford, MA USA
[3] Novartis, Florham Pk, NJ USA
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A270 / A270
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF ADJUVANT IMATINIB IN PATIENTS WITH SURGICALLY RESECTED LOCALIZED GASTROINTESTINAL STROMAL TUMORS (GIST): CANADIAN SOCIETAL PERSPECTIVE
    Pawar, V.
    El Ouagari, K.
    Rubin, J.
    Coombs, J. H.
    Taylor, D.
    ANNALS OF ONCOLOGY, 2010, 21 : 232 - 232
  • [2] COST-EFFECTIVENESS OF IMATINIB IN THE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST): CANADIAN PERSPECTIVE
    El Ouagari, K.
    Huse, D. M.
    ANNALS OF ONCOLOGY, 2008, 19 : 227 - 227
  • [3] Cost-effectiveness of three years of adjuvant imatinib in gastrointestinal stromal tumors (GIST).
    Sanon, Myrlene
    Parthan, Anju
    Taylor, Douglas
    Coombs, John
    Paolantonio, Marc
    Sasane, Medha
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [4] Cost-effectiveness of adjuvant imatinib in intermediate-risk gastrointestinal stromal tumors (GIST)
    Wu, Victoria S.
    Schiltz, Nicholas
    Zhao, Jack
    Winter, Jordan M.
    Hoehn, Richard S.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S265 - S265
  • [5] COST-EFFECTIVENESS OF THREE-YEARS OF ADJUVANT IMATINIB IN GASTROINTESTINAL STROMAL TUMORS (GIST) IN CANADA
    Parthan, A.
    Sanon, M.
    Coombs, J.
    El Ouagari, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 235 - 235
  • [6] Cost-effectiveness (CE) of imatinib (IM) in the treatment of advanced gastrointestinal stromal tumors (GIST)
    Huse, Daniel
    Lenhart, Greg
    Feng, Weiwei
    Blanke, Charles
    Joensuu, Heikki
    Mehren, Margaret V.
    Demetri, George D.
    ANNALS OF ONCOLOGY, 2006, 17 : 162 - 162
  • [7] A COST-EFFECTIVENESS ANALYSIS OF THREE YEARS OF ADJUVANT IMATINIB IN KIT plus GASTROINTESTINAL STROMAL TUMORS (GIST) IN GREECE
    Raikou, M.
    Boukovinas, I.
    Geitona, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 236 - 236
  • [8] TREATMENT PATTERNS AND COST OF CARE FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST) TREATED WITH IMATINIB
    Seal, B. S.
    Xia, F.
    Stafkey-Mailey, D.
    Asche, C.
    Zagadailov, E.
    Eaddy, M.
    VALUE IN HEALTH, 2014, 17 (03) : A81 - A82
  • [9] COST-EFFECTIVENESS OF SUNITINIB plus BEST SUPPORTIVE CARE FOR THE TREATMENT OF UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS IN MEXICO
    Chi-Chan, A.
    Gutierrez-Colin, C., I
    Peniche-Otero, G.
    Herrera-Rojas, J.
    Mucino, E.
    Galindo-Suarez, R. M.
    VALUE IN HEALTH, 2012, 15 (04) : A218 - A218
  • [10] Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany
    Tamoschus, David
    Draexler, Katja
    Chang, Jane
    Ngai, Christopher
    Madin-Warburton, Matthew
    Pitcher, Ashley
    CLINICAL DRUG INVESTIGATION, 2017, 37 (06) : 525 - 533
12345